menu
App Logo

Menu

close
Home
/
All Categories
/
AML News

AML News

Here you will find articles that discuss the latest advances in AML. You will be kept up to date on the newest FDA drug approvals for AML drugs and treatment combinations. You will also learn about newly published research studies and any advances or findings that may contribute to your AML treatment. We will discuss topics such as newly discovered AML genetic mutations, exciting advances on new therapies like CAR-T therapy and NK cells, and improvements in alloegenic stem cell transplant. 

 

Articles posted here will also aim to help answer common questions like "how is AML treated?", "how is AML diagnosed?", and "what causes AML?". 

 

With new AML research being published almost every day, there is a lot to keep track of. The articles in this category will help you stay informed of new AML treatment options and AML research findings which will ultimately make you an empowered patient. Being empowered allows you to take important information to your healthcare team for discussion that will further enhance and personalize your care. 

Article Category Image
List-tile-article

January is National Blood Donor Month

This January is a time of critical blood shortage. Let's raise awareness about the crucial role blood donations play in saving and lengthening the lives of those with acute myeloid leukemia. Share this article with friends and family to encourage them to donate blood!
List-tile-article

ASH 2021: Dr. Eunice Wang on Searching for the Most Effective Treatment for Newly Diagnosed FLT3 Positive AML

Dr. Eunice Wang, an AML specialist from Roswell Park Comprehensive Cancer Center in New York discusses the interim results of the phase 3 LACEWING trial looking at the use of gilteritinib + azacitidine vs azacitidine alone in newly diagnosed FLT3 positive AML patients.

List-tile-article

Introducing Side Effect Solutions, A Patient-Centric Tool to Find Relief and Help Others

New year, new tool from HealthTree! Introducing Side Effect Solutions, a place where you as a patient can contribute your solution. You can add your solutions for each side effect you experience to contribute to important data collection and patient-centric learning. This tool arms patients with the information they need to discuss their individual situation and health with their doctor.

List-tile-article

ASH 2021: Code Status Transitions in Patients with High-Risk AML & Why End of Life Discussions are Important

Kerith Amen, who was an AML caregiver to her husband Rob, describes a study presented at ASH looking at end-of life care discussions that brought back memories from her experience. The study revealed that these important conversations aren’t taking place often enough and in many cases, a change in code status is occurring late in the course of the illness and patients may not be able to participate. It is Kerith's hope that Rob’s story and this study encourage and empower patients and caregivers to open the lines of communication about what is important to them in their end-of-life care.

List-tile-article

ASH 2021: Menin Inhibitors on the Horizon for NPM1 Mutated AML

On Monday December 13th, 2021 at the ASH conference, Dr. Eytan Stein, an AML expert from Memorial Sloane Kettering in New York City describes his exciting work on a menin inhibitor called SNDX-5613. for NPM1 mutated AML.
List-tile-article

ASH 2021: Dr. Andrew Hantel on Understanding and Addressing Disparities in AML Clinical Trials

Dr. Andrew Hantel, an AML expert from Dana-Farber Cancer Institute in Boston, Mass shared his oral abstract titled Race-Ethnic Enrollment Disparities over 15 Years of Alliance/CALGB Acute Myeloid Leukemia Clinical Trials, Biobanks, and Correlative Science Protocols and visited with us afterward to explain the study and his findings.
List-tile-article

ASH 2021: Response to COVID-19 Vaccines in Patients with AML

Dr. Akriti Jain from H. Lee Moffitt Cancer Center and Research Institute presented her abstract today at ASH 2021 titled Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia highlighting that the majority of AML patients benefited from high response rates from mRNA COVID-19 vaccines, especially after receiving the second dose.
List-tile-article

ASH 2021: AML: So Many Options, So Little Time Q&A Session

The landscape of advances in AML therapy has rapidly expanded over the last few years, and there is definitely a lot to talk about in terms of medication use this year at ASH. We attended a Q&A session with Dr. Felicitas Thol, Dr. Christian Thiede and Dr. Margaret Kasner as they took questions from the audience about how they approach the use of various AML medications and MRD testing. 
List-tile-article

ASH 2021 Friday Symposium: Seizing Opportunity in AML 

Every Friday before the annual American Society of Hematology (ASH) meeting features a variety of symposia that feature current treatment practices for every type of hematological disease and malignancy. Today we kicked off the 2021 ASH annual conference in Atlanta, Georgia by attending a satellite symposium hosted by PeerView that featured AML experts Dr. Daver, Dr. DiNardo, Dr. Borate and Dr. Stein.
List-tile-article

ASH 2021: HealthTree for AML has ASH Covered

The American Society of Hematology (ASH) annual meeting starts next Friday, and we will be there to share with you the newest advances in acute myeloid leukemia. ASH 2021 is the most important meeting of the year for medical professionals to come together to learn about the best AML research taking place. Check our website daily for the latest ASH news and updates!

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Follow Us

facebook instagram twitter youtube

 

Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect

 

Copyright © 2021 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811